|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZRANB3 |
Gene summary for ZRANB3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZRANB3 | Gene ID | 84083 |
| Gene name | zinc finger RANBP2-type containing 3 | |
| Gene Alias | 4933425L19Rik | |
| Cytomap | 2q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | Q5FWF4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84083 | ZRANB3 | CCI_1 | Human | Cervix | CC | 9.95e-04 | 5.13e-01 | 0.528 |
| 84083 | ZRANB3 | CCI_2 | Human | Cervix | CC | 3.18e-05 | 5.77e-01 | 0.5249 |
| 84083 | ZRANB3 | CCI_3 | Human | Cervix | CC | 3.63e-06 | 5.46e-01 | 0.516 |
| 84083 | ZRANB3 | AEH-subject1 | Human | Endometrium | AEH | 4.32e-06 | 2.46e-01 | -0.3059 |
| 84083 | ZRANB3 | AEH-subject5 | Human | Endometrium | AEH | 9.13e-03 | 1.89e-01 | -0.2953 |
| 84083 | ZRANB3 | EEC-subject1 | Human | Endometrium | EEC | 1.78e-02 | 2.54e-01 | -0.2682 |
| 84083 | ZRANB3 | EEC-subject2 | Human | Endometrium | EEC | 4.07e-02 | 1.92e-01 | -0.2607 |
| 84083 | ZRANB3 | NAFLD1 | Human | Liver | NAFLD | 2.31e-04 | 6.20e-01 | -0.04 |
| 84083 | ZRANB3 | HCC1_Meng | Human | Liver | HCC | 7.44e-26 | -3.22e-02 | 0.0246 |
| 84083 | ZRANB3 | HCC1 | Human | Liver | HCC | 5.94e-04 | 1.16e+00 | 0.5336 |
| 84083 | ZRANB3 | HCC2 | Human | Liver | HCC | 2.71e-09 | 1.25e+00 | 0.5341 |
| 84083 | ZRANB3 | HTA12-15-2 | Human | Pancreas | PDAC | 4.06e-02 | 2.34e-01 | 0.2315 |
| 84083 | ZRANB3 | HTA12-23-1 | Human | Pancreas | PDAC | 1.44e-05 | 5.98e-01 | 0.3405 |
| 84083 | ZRANB3 | HTA12-25-1 | Human | Pancreas | PDAC | 3.65e-03 | 3.88e-01 | 0.313 |
| 84083 | ZRANB3 | HTA12-26-1 | Human | Pancreas | PDAC | 9.77e-13 | 5.40e-01 | 0.3728 |
| 84083 | ZRANB3 | HTA12-29-1 | Human | Pancreas | PDAC | 6.38e-18 | 4.35e-01 | 0.3722 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00093149 | Cervix | CC | response to radiation | 86/2311 | 456/18723 | 3.50e-05 | 5.63e-04 | 86 |
| GO:00094112 | Cervix | CC | response to UV | 33/2311 | 149/18723 | 5.51e-04 | 5.29e-03 | 33 |
| GO:00510528 | Cervix | CC | regulation of DNA metabolic process | 65/2311 | 359/18723 | 9.25e-04 | 7.84e-03 | 65 |
| GO:00062602 | Cervix | CC | DNA replication | 48/2311 | 260/18723 | 2.70e-03 | 1.85e-02 | 48 |
| GO:00323923 | Cervix | CC | DNA geometric change | 21/2311 | 90/18723 | 2.71e-03 | 1.85e-02 | 21 |
| GO:00094163 | Cervix | CC | response to light stimulus | 54/2311 | 320/18723 | 1.03e-02 | 4.97e-02 | 54 |
| GO:000931410 | Endometrium | AEH | response to radiation | 70/2100 | 456/18723 | 3.99e-03 | 2.68e-02 | 70 |
| GO:00062752 | Endometrium | AEH | regulation of DNA replication | 21/2100 | 107/18723 | 7.38e-03 | 4.20e-02 | 21 |
| GO:000627511 | Endometrium | EEC | regulation of DNA replication | 22/2168 | 107/18723 | 5.09e-03 | 3.20e-02 | 22 |
| GO:000931413 | Endometrium | EEC | response to radiation | 71/2168 | 456/18723 | 5.69e-03 | 3.42e-02 | 71 |
| GO:0051053 | Liver | NAFLD | negative regulation of DNA metabolic process | 26/1882 | 125/18723 | 2.52e-04 | 4.12e-03 | 26 |
| GO:00510526 | Liver | NAFLD | regulation of DNA metabolic process | 56/1882 | 359/18723 | 5.95e-04 | 7.92e-03 | 56 |
| GO:00323922 | Liver | NAFLD | DNA geometric change | 18/1882 | 90/18723 | 3.34e-03 | 2.93e-02 | 18 |
| GO:0090305 | Liver | HCC | nucleic acid phosphodiester bond hydrolysis | 152/7958 | 261/18723 | 1.90e-07 | 3.46e-06 | 152 |
| GO:005105221 | Liver | HCC | regulation of DNA metabolic process | 198/7958 | 359/18723 | 7.62e-07 | 1.17e-05 | 198 |
| GO:00062601 | Liver | HCC | DNA replication | 146/7958 | 260/18723 | 5.68e-06 | 7.02e-05 | 146 |
| GO:0009411 | Liver | HCC | response to UV | 85/7958 | 149/18723 | 2.34e-04 | 1.77e-03 | 85 |
| GO:003239211 | Liver | HCC | DNA geometric change | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
| GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
| GO:00062751 | Liver | HCC | regulation of DNA replication | 60/7958 | 107/18723 | 3.15e-03 | 1.46e-02 | 60 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZRANB3 | SNV | Missense_Mutation | c.635N>A | p.Arg212Lys | p.R212K | Q5FWF4 | protein_coding | deleterious(0.05) | benign(0.006) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| ZRANB3 | SNV | Missense_Mutation | c.1598N>T | p.Arg533Ile | p.R533I | Q5FWF4 | protein_coding | deleterious(0.03) | benign(0.316) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZRANB3 | SNV | Missense_Mutation | c.430G>C | p.Asp144His | p.D144H | Q5FWF4 | protein_coding | tolerated(0.07) | probably_damaging(0.909) | TCGA-AR-A1AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| ZRANB3 | SNV | Missense_Mutation | c.1771G>C | p.Glu591Gln | p.E591Q | Q5FWF4 | protein_coding | tolerated(0.3) | benign(0.012) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZRANB3 | SNV | Missense_Mutation | novel | c.3105N>A | p.Asp1035Glu | p.D1035E | Q5FWF4 | protein_coding | tolerated(0.44) | benign(0.006) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZRANB3 | SNV | Missense_Mutation | c.3234N>T | p.Lys1078Asn | p.K1078N | Q5FWF4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.981) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| ZRANB3 | SNV | Missense_Mutation | c.1720N>A | p.Glu574Lys | p.E574K | Q5FWF4 | protein_coding | deleterious(0.04) | benign(0.01) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZRANB3 | SNV | Missense_Mutation | c.2861G>A | p.Arg954Lys | p.R954K | Q5FWF4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZRANB3 | SNV | Missense_Mutation | c.3206N>T | p.Gly1069Val | p.G1069V | Q5FWF4 | protein_coding | deleterious(0) | possibly_damaging(0.642) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| ZRANB3 | insertion | Frame_Shift_Ins | novel | c.1279_1280insAGATGGGTGGATCACCTGAGGTCAGGAGTTCGAGACTAGCC | p.Ala427GlufsTer28 | p.A427Efs*28 | Q5FWF4 | protein_coding | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |